Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

Phase 1 Completed 32 enrolled Chong Kun Dang Pharmaceutical

RandomizedCrossoverOpen-labelTreatment

Summary

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150 for Healthy Subjects in Fed State

Timeline

Start: 2023-05-26
Primary completion: 2023-06-04
Completion: 2023-06-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CKD-383	Unknown	—	Oral
Subject	D150	Unknown	—	Oral
Subject	D744	Unknown	—	Oral
Subject	Lobeglitazone	Small molecule	—	Oral

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

Summary

Timeline

Drugs

Indications